A Phase 1 interventional study of Nemolizumab and Nemolizumab in Healthy Volunteers, sponsored by Galderma R&D. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is the only one that started in 2022, is the only one in phase 1, and was the 11th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
17 studies in Dermatitis, Atopic by Galderma Group AG: 3 open now, 3 under way, 1 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1, and was the 14th registered.
Galderma Group AG’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
Among Galderma Group AG’s 17 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 60 milligrams (mg) dose of nemolizumab as 2 successive subcutaneous (SC) injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 centimeters \[cm\]) apart with AI on Day 0 (injection day).
Drug: Nemolizumab
Participants received a 60-mg dose of nemolizumab as 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with DCS on Day 0 (injection day).
Drug: Nemolizumab
Nemolizumab with Auto-Injector (AI).
Nemolizumab with Dual-Chamber Syringe (DCS).
Maximum Observed Plasma Concentration (Cmax) of Nemolizumab
Cmax was defined as the observed maximum serum concentration of nemolizumab. Cmax was used to measure the rate of absorption of nemolizumab.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab
AUC0-inf was defined as area under the plasma concentration-time curve from time 0 to infinity according to the equation: AUC0-inf = AUClast + Clast/λz; where λz = slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale; and Clast = last measurable drug concentration.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Area Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab
AUC0-4 weeks was defined as area under the concentration-time curve from time 0 to 4 weeks after study drug administration calculated with the linear trapezoidal method.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22 and 29 post-dose
Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab
AUC0-last was defined as area under the concentration-time curve from administration to the last observed concentration time t, calculated with the linear trapezoidal method.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab
Tmax was defined as the time taken to reach the maximum observed serum concentration.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Half-life (t1/2) of Nemolizumab
t1/2 is defined as time required for the concentration of the drug to reach half of its original value.
Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Number of Participants With Positive Anti-drug Antibodies (ADA) Response Against Nemolizumab
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
Time frame: Pre-dose, Day 29 and 85 post-dose
The study was conducted at 2 sites in United States from 11 August 2022 to 08 December 2022.
| Milestone | Nemolizumab With Auto-Injector (AI) | Nemolizumab With Dual Chamber Syringe (DCS) |
|---|---|---|
| Started | 96 | 96 |
| Completed | 95 | 96 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Cmax was defined as the observed maximum serum concentration of nemolizumab. Cmax was used to measure the rate of absorption of nemolizumab.
| micrograms per milliliter (mcg/mL) | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Nemolizumab | 8.00 ± 2.34 | 7.51 ± 2.31 |
AUC0-inf was defined as area under the plasma concentration-time curve from time 0 to infinity according to the equation: AUC0-inf = AUClast + Clast/λz; where λz = slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale; and Clast = last measurable drug concentration.
| micrograms*day per milliliter | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab | 270 ± 85.8 | 279 ± 89.7 |
AUC0-4 weeks was defined as area under the concentration-time curve from time 0 to 4 weeks after study drug administration calculated with the linear trapezoidal method.
| micrograms*day per milliliter | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Area Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab | 157 ± 37.9 | 155 ± 39.8 |
AUC0-last was defined as area under the concentration-time curve from administration to the last observed concentration time t, calculated with the linear trapezoidal method.
| micrograms*day per milliliter | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab | 250 ± 73.6 | 260 ± 75.4 |
Tmax was defined as the time taken to reach the maximum observed serum concentration.
| days | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab | 4.99 (1.00 to 21.99) | 5.99 (1.00 to 22.00) |
t1/2 is defined as time required for the concentration of the drug to reach half of its original value.
| days | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Half-life (t1/2) of Nemolizumab | 18.0 ± 5.91 | 18.5 ± 4.52 |
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
| Participants | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| Pre-dose: ADA postive | 6 | 8 |
| Day 29: ADA positive | 2 | 4 |
| Day 85: ADA positive | 2 | 8 |
Collected over From Baseline up to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nemolizumab With AI | 0/96 (0%) | 0/96 (0%) | 41/96 (42.7%) |
| Nemolizumab With DCS | 0/96 (0%) | 0/96 (0%) | 54/96 (56.3%) |
| Event | Nemolizumab With AI | Nemolizumab With DCS |
|---|---|---|
| HeadacheNervous system disorders | 8/96 | 22/96 |
| Weight increasedInvestigations | 7/96 | 5/96 |
| Back painMusculoskeletal and connective tissue disorders | 1/96 | 5/96 |
| PruritusSkin and subcutaneous tissue disorders | 1/96 | 5/96 |
| NauseaGastrointestinal disorders | 2/96 | 4/96 |
| PapuleSkin and subcutaneous tissue disorders | 1/96 | 4/96 |
| Viral infectionInfections and infestations | 0/96 | 3/96 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/96 | 3/96 |
| ErythemaSkin and subcutaneous tissue disorders | 3/96 | 0/96 |
| PalpitationsCardiac disorders | 0/96 | 2/96 |
Analysis was performed on safety population that included all randomized participants who received the single dose of nemolizumab and was the primary population for all safety data.
| Age, Continuous(years) | Nemolizumab With AI | Nemolizumab With DCS | Total |
|---|---|---|---|
| Mean | 40.9 ± 11.71 | 42.1 ± 12.52 | 41.5 ± 12.11 |
| Sex: Female, Male(Participants) | Nemolizumab With AI | Nemolizumab With DCS | Total |
|---|---|---|---|
| Female | 55 | 62 | 117 |
| Male | 41 | 34 | 75 |
| Ethnicity (NIH/OMB)(Participants) | Nemolizumab With AI | Nemolizumab With DCS | Total |
|---|---|---|---|
| Hispanic or Latino | 53 | 51 | 104 |
| Not Hispanic or Latino | 43 | 45 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nemolizumab With AI | Nemolizumab With DCS | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 8 | 17 |
| White | 82 | 80 | 162 |
| More than one race | 4 | 5 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Nov 2022, 3 months.
Results were first posted in Jan 2025, 2 years 1 month after primary completion.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 3 months is below that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab